Eureka Therapeutics will pay JW Therapeutics $10M upfront and up to $100M in milestones for GPC3 and AFP TCR-T rights in ...
Addex spinout Neurosterix closes a USD 105M Series B to advance NTX-253 into Phase II. Read the full story on this ...
See how ImvivaBio's CTA313 CD19/BCMA allogeneic CAR-T sustained responses in refractory lupus, including nephritis, as it ...
Protagenic (PTIX) raises $1.5M in a private placement to advance PT00114 into a U.S. anxiety trial after its Phytanix ...
Flagship Pioneering and Gates Foundation launch a $25M global health unit to fund health and agriculture solutions for ...
Bristol Myers Squibb will merge research and development into one end-to-end organization from January 1, 2027. Learn how ...
Pfizer and Blackstone Life Sciences strike a $1.5B co-funding deal for an obesity drug as Pfizer trims its pipeline. Read the ...
China's NMPA approves Hengrui's rivocibart (SHR-1918) for homozygous familial hypercholesterolemia in patients aged 12 and older. Read the full story now.
Scripps Research and 23andMe Research Institute launch genetics-based recruitment for an Alzheimer's prevention trial. Check if you qualify to join today.
Nimbus Therapeutics has dosed healthy volunteers with NDI-225673, a selective SIK2 inhibitor for inflammatory diseases. Read more about the Phase I trial.
Ocugen licenses OCU400, Phase III gene therapy for retinitis pigmentosa, to Celairis for Australia, NZ and ASEAN. See the ...
PepGen's PGN-EDODM1 corrected muscle splicing and improved myotonia in a six-patient Phase II DM1 cohort with no serious ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results